Umar Faruk Saidu

Mr. Umar Faruk Saidu

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Clinical and Experimental Vaccine Research
Verified
Journal Article
Open access
PDF file
BEBlessing Nkechi Emmanuel
Blessing Nkechi Emmanuel
AIAbubakar Nuhu Ishaq
Abubakar Nuhu Ishaq
OAOlisaemeka Zikora Akunne
Olisaemeka Zikora Akunne
USUmar Faruk Saidu
Umar Faruk Saidu
Emmanuel BN, et al. Clin Exp Vaccine Res. 2024 Apr;13(2):121-131. https://doi.org/10.7774/cevr.2024.13.2.121

12 February 2024 in Experimental and Applied Medical Science
Verified
Journal Article
Open access
IBIbrahim Bulama
Ibrahim Bulama
USUmar Faruk Saidu
Umar Faruk Saidu
NSNasiru Sulei̇man
Nasiru Sulei̇man
AAAbdullahi Abbas
Abdullahi Abbas
YSYusuf Sai̇du
Yusuf Sai̇du
LBLawal Bi̇lbi̇s
Lawal Bi̇lbi̇s
Objective: Traumatic brain injury (TBI) is a major cause of mortality and disability worldwide. This study was designed to investigate the beneficial and neuroprotective role of some Low-Molecular-Weight antioxidants (LMWA) in the treatment of TBI in albino rats. Methods: TBI was induced in adult albino rats using the weight-drop method. A total of 70 Rats was used and were divided into 12 treatment groups, a traumatized non-treated group (TNT) and a Non-traumatized non-treated group (NTNT). There were 5 rats per group. Each of the treatment groups received 22.5 or 45 mg/kg of dimethyl sulfoxide (DMSO), Alpha Lipoic acid (ALA), Uric acid (UA), vitamin C (VC), vitamin E (VE), or Mannitol. Treatment was started 30 min after the trauma and continued for 21 days. To evaluate the functional outcomes, the modified neurological severity score (mNSS) was calculated. The antioxidant enzymes [superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx)], and malondialdehyde (MDA) were assayed to evaluate oxidative stress (OS). Results: At 7 days post-TBI, the antioxidant-treated groups exhibited significant (p

14 October 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
USUmar Faruk Saidu
Umar Faruk Saidu
IBIbrahim Bulama
Ibrahim Bulama
Traumatic brain injury (TBI) is a significant cause of morbidity and mortality worldwide, with long-term neurological and psychological impacts. Recent studies have indicated that diabetes (T1DM) exacerbates the outcomes of TBI, leading to more severe cognitive deficits and increased risk of complications. This study investigated the underlying molecular mechanisms and potential therapeutic targets for T1DM-associated TBI. Four mRNA datasets (GSE4745, GSE125451, GSE173975, and GSE80174) downloaded from GEO repository were used in this study. Using limma, a total of 284 differentially expressed genes (DEGs) were identified in T1DM, of which 11 were upregulated and 9 were downregulated. GSEA showed that these DEGs were significantly enriched in cell communication, lipid metabolic process, and PPAR signaling. A total of 584 DEGs were identified in TBI, of which 186 were upregulated and 9 were downregulated. GSEA showed that these DEGs were mainly enriched in immune response-regulating signaling pathway. WGCNA identified 122 significant genes in TIDM-related modules and 368 significant genes in TBI-related module. GO and KEGG enrichment analysis showed that T1DM module genes were significantly correlated with lipid metabolic process and ribosome biogenesis, while TBI module genes were significantly correlated with inflammation and immune response, including leukocyte mediated immunity, lymphocyte mediated immunity, and cytokine mediated receptor activity. PPI network analysis of T1DM module genes identified 20 hub genes, including 14 ribosomal genes: Rpl23, Rps3a, Rps6, Rpl5, Rpl17, Rps24, Rpl23a, Rps4x, Rpl9, Rps15a14, Rpl30, Rpl31, Rps25, and Rps27a-2. The hub genes were primarily related to ribosome biogenesis and RNA post-transcriptional regulation. PPI network analysis of TBI module genes identified 20 hub genes: Ptprc, Tp53, Stat1, Stat3, Tyrobp, Itgad, Csf1r, Itgb2, Rac2, Icam1, Myd88, Cd44, Vav1, Aif1, C1qa, Laptm5, B2m, Fcer1g, and Lyn. The hub genes were primarily related to inflammatory mediators and immune response. Based on the overlap of T1DM module genes and TBI module genes, Cmklr1, Mgst1, and Plin2, were identified as key genes of T1DM-associated TBI. Functional enrichment analysis showed that they were primarily enriched in the cellular response to hydroperoxide, cytokine-mediated receptor signaling activity, regulation of sequestering of triglyceride, negative regulation of IL-12 production, and positive regulation of macrophage chemotaxis. Using Reactome, Cmklr1, Mgst1, and Plin2 were related to cytokine signaling activity, neutrophil degranulation, and lipid storage, respectively. We concluded that Lipid droplet dysregulation and Neuroinflammation are the potential molecular mechanisms of T1DM-associated TBI. Cmklr1, Mgst1, and Plin2 are positively correlated with T1DM-associated TBI and may be important biomarkers and potential treatment targets for diabetic TBI.

21 January 2026 in American Journal of Pharmacotherapy and Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
NSNasiru Suleiman
Nasiru Suleiman
FSFatima Sanusi
Fatima Sanusi
IBIbrahim Bulama
Ibrahim Bulama
USUmar Faruk Saidu
Umar Faruk Saidu
YIYusuf Idris
Yusuf Idris
LBLawal Suleman Bilbis
Lawal Suleman Bilbis
Stroke is a significant global health challenge, causing substantial mortality and disability worldwide, with its prevalence rising particularly in low- and middle-income countries. This review discusses the role of inflammatory cells in ischemic stroke (IS), the limitations of conventional drugs, and the emerging potential of plant-derived medications. Drawing from extensive research, it highlights recent findings on neuroinflammation and neuroprotective strategies using natural compounds. IS triggers a complex inflammatory response involving microglia, astrocytes, and leukocytes, which significantly contributes to secondary tissue damage; understanding this interplay is crucial for developing effective interventions. Conventional drugs, such as recombinant tissue plasminogen activator and antiplatelet agents, face limitations including a narrow therapeutic window and the risk of hemorrhagic transformation, underscoring the need for alternative approaches. Plant-derived medications show considerable promise due to their neuroprotective effects and ability to modulate inflammatory pathways. Bioactive compounds such as flavonoids and polyphenols offer potent antioxidant and anti-inflammatory properties, which may improve treatment outcomes. Recent research has unveiled their mechanisms of action, which include reducing oxidative stress, neuroinflammation, and promoting neurogenesis, suggesting a strong potential to mitigate neuronal damage and aid post-stroke recovery. Exploring plant-derived medications represents a paradigm shift toward utilizing natural compounds for stroke management. By tapping into the vast pharmacological potential of plants, researchers aim to develop safer and more effective therapies that overcome the limitations of conventional drugs. These advancements offer hope for improving IS management and reducing its global burden. Continued research is crucial to unlock these innovative therapeutic strategies and enhance patient outcomes worldwide.